As a next-generation cancer immunotherapeutic strategy, antibody-drug conjugates (ADCs) combines the targeting specificity of a monoclonal antibody with the high toxicity of a payload drug to achieve discriminated cancer cell elimination. Payload drugs disrupt important cellular pathways and result in cell death by apoptosis. Microtubule is a key intracellular target for a variety of payload drugs. With a deep understanding of the payload structure, chemistry, and effects, Creative Biolabs provides customized ADCs development using microtubule toxins as payloads, which include auristatins, epothilone, maytansinoids, taxoids, tubulysins, and vinorelbine.